Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥302,000 million, core operating profit of ¥58,000 million, core net profit for the year of ¥43,500 million and basic core earnings per share of ¥118.87 compared to the previous guidance of revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 provided earlier.

On IFRS basis, the company expects revenue of ¥302,000 million, operating profit of ¥41,000 million, net profit for the year of ¥29,500 million and basic earnings per share of ¥80.64 compared to the previous guidance of guidance of revenue of ¥285,000 million, core operating profit of ¥35,000 million, core net profit for the year of ¥25,000 million and basic core earnings per share of ¥68.34 provided earlier.